Pull to refresh
Logo
Viking's obesity drug moves most patients down a BMI class in mid-stage trial

Viking's obesity drug moves most patients down a BMI class in mid-stage trial

New Capabilities

VK2735 data at ObesityWeek show 74% improved at least one BMI category versus 15% on placebo

Overview

Updated 3 hours ago

Seventy-four percent of people who took Viking Therapeutics' experimental obesity drug for 13 weeks dropped at least one body mass index class. Among those on placebo, 15% did.

The data, presented at ObesityWeek 2026 in Washington, D.C., come from a mid-stage trial of 176 people. Viking is now running two 78-week Phase 3 trials that will decide whether VK2735 can challenge the two drugs that currently dominate obesity treatment.

Why it matters

A third weekly obesity injection would give patients and insurers another option in a market now split between Novo Nordisk and Eli Lilly.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

74%
VK2735 participants improving ≥1 BMI class
104 of 140 participants on combined VK2735 doses after 13 weeks.
15%
Placebo participants improving ≥1 BMI class
5 of 34 placebo participants over the same period.
14.7%
Mean weight reduction at highest dose
15 mg weekly dose over 13 weeks in the Phase 2 VENTURE trial.
9.1%
Mean weight reduction at lowest dose
2.5 mg weekly dose over 13 weeks.
93%
Participants losing ≥5% body weight
130 of 140 on active treatment, versus 12% on placebo.
78 weeks
Phase 3 treatment duration
Length of the VANQUISH-1 and VANQUISH-2 trials.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

February 2024 November 2026

6 events Latest: Today
Tap a bar to jump to that date
  1. Viking presents BMI-category and cardiometabolic data

    Today Conference presentation

    74% of VK2735 participants improved at least one BMI class versus 15% on placebo; no treated participant worsened.

  2. Viking announces two ObesityWeek posters

    Announcement

    Company flagged presentations on the VENTURE BMI analysis and VANQUISH-2 baseline characteristics.

  3. Viking reports positive Part 1 maintenance data

    Company update

    Third-quarter update cited positive results from Part 1 of a two-part VK2735 maintenance study.

  4. VENTURE results published in the journal Obesity

    Publication

    Peer-reviewed results showed mean weight reductions of 9.1% to 14.7% across doses versus 1.7% on placebo.

  5. Viking launches Phase 3 VANQUISH program

    Clinical trial

    Two 78-week trials: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes.

  6. VENTURE Phase 2 completes 13-week dosing

    Clinical trial

    The 176-participant trial ran from August 2023 to February 2024, testing weekly subcutaneous VK2735 at 2.5 to 15 mg.

Scenarios

1

VANQUISH Phase 3 meets its primary endpoint and Viking files for approval

Possible Resolves by Q2 2028

Discussed by: Viking Therapeutics and clinical-trial observers tracking the 2027 readout

If the 78-week Phase 3 trials reproduce the Phase 2 weight-loss signal with tolerable side effects, Viking would submit a New Drug Application to the Food and Drug Administration. That would put a third weekly injection into the U.S. obesity market.

2

A large pharmaceutical company acquires Viking before Phase 3 reads out

Possible Resolves by Q2 2027

Discussed by: Biotech investors and sector analysts

A positive mid-stage profile can make a clinical-stage company a takeover target before its most expensive trial finishes. An acquirer would gain VK2735 and Viking's oral formulation work.

3

Phase 3 fails to separate from placebo on weight loss

Unlikely Resolves by End of 2027

Discussed by: Clinical-trial watchers noting that mid-stage results often shrink at larger scale

Phase 2 trials enroll fewer people and can overstate an effect. If the 78-week trials show no statistically significant difference from placebo on the primary endpoint, the program would stall.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

June 2021

Wegovy approval opens the GLP-1 obesity market (2021)

The Food and Drug Administration approved semaglutide, sold as Wegovy, for chronic weight management. It was the first GLP-1 receptor agonist cleared specifically for obesity in the U.S.

Then

Demand outstripped supply, and the drug became a cultural phenomenon.

Now

It established a multi-billion-dollar market that pulled rival drugmakers into obesity research.

Why this matters now

VK2735 would enter the market Wegovy created, competing on the same GLP-1 mechanism plus an added GIP target.

September 1997

Fen-phen withdrawal (1997)

The FDA asked manufacturers to withdraw fenfluramine after reports linked the fen-phen combination to heart-valve damage. The episode chilled obesity drug development for years.

Then

Millions of patients stopped the drug, and lawsuits followed.

Now

Regulators began demanding cardiovascular safety data from obesity drugs, raising the bar for approval.

Why this matters now

It explains why modern obesity trials, including Viking's Phase 3, run for 78 weeks and track cardiometabolic markers, not just weight.

November 2023

Zepbound approval validates the dual GIP/GLP-1 approach (2023)

The FDA approved Eli Lilly's tirzepatide, sold as Zepbound, for weight management. It targets both the GIP and GLP-1 receptors.

Then

Zepbound became the main competitor to Wegovy.

Now

It proved a dual-receptor drug could win regulatory approval, opening the path Viking is now following.

Why this matters now

VK2735 uses the same dual-receptor strategy as Zepbound, making Lilly both a template and a rival.

Sources

(6)